FOXP3 and systemic lupus erythematosus: These findings offer preliminary insights into the immunomodulatory actions of JPZS and shed light on a potential epigenetic regulatory mechanism, involving the DNMT1-Foxp3 axis, that may contribute to its therapeutic effects in this experimental model of SLE.